MedPath

Effect van fosfaat verlaging op FGF23 en bloedvaten.Effect of phosphate reduction on FGF23 and bloodvessel function.

Recruiting
Registration Number
NL-OMON25966
Lead Sponsor
Vrije Universiteit Medisch Centrum (VUmc) Amsterdam
Brief Summary

/A

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

1. Patients with eGFR 30-60 ml/min/1,73 m2;

2. Serum phosphorus level <1,49 mmol/L and >1,0 mmol/L;

Exclusion Criteria

1. Known allergy or intolerance for sevelamer-containing drugs;

2. Patients with heart failure;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum FGF23 and phosphaturia before and after 8 weeks of treatment with sevelamer-carbonate.
Secondary Outcome Measures
NameTimeMethod
Pulse Wave Velocity measured before and after the treatment with Sevelamer.
© Copyright 2025. All Rights Reserved by MedPath